RxDoctor Payments Data

Marcella Pipitone

Optometrist · Kent, OHNPI 1275910259

Payments from drug & device makers

$10,253in general payments, 2019–2025

Across 218 payments — averaging $47.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$5K
  • AbbVie$1K
  • Coopervision Inc.$818
  • Alcon$675
  • Bausch & Lomb Americas Inc.$279
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$233
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$4,74446%
  • Travel & lodging$7327%
  • Food & beverage$4,71946%
  • Education$581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,253 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$130,036
Medicare patients
561
Services billed
1,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost253$155,438
RestasisCyclosporine33$47,810
RhopressaNetarsudil Mesylate58$33,171
RocklatanNetarsudil Mesylat/Latanoprost37$25,779
VyzultaLatanoprostene Bunod49$19,190
Brimonidine Tartrate314$17,920
CombiganBrimonidine Tartrate/Timolol56$17,391
Latanoprost908$11,725
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat480$9,061
SimbrinzaBrinzolamide/Brimonidine Tart37$8,469
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$8,399
Travoprost23$7,813
Alphagan PBrimonidine Tartrate16$7,047
Bimatoprost41$5,915
Brinzolamide26$5,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,224$227,686358 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$5,217$58,95095 claims
Bausch & Lomb Americas Inc.Vyzulta$279$19,19049 claims
AlconSimbrinza$675$8,46937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Kent

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →